Dr. Sarah Sinclair, DO, Oncology ...

Dr. Sarah J. Sinclair

Claim this profile

Lafayette Family Cancer Center-EMMC

Expert in Breast Cancer
Expert in Lung Cancer
80 reported clinical trials
157 drugs studied

Area of expertise

1Breast Cancer
Global Leader
Sarah J. Sinclair has run 19 trials for Breast Cancer. Some of their research focus areas include:
HER2 positive
ER positive
Stage IV
2Lung Cancer
Global Leader
Sarah J. Sinclair has run 14 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Affiliated Hospitals

Image of trial facility.
Lafayette Family Cancer Center-EMMC
Image of trial facility.
Eastern Maine Medical Center

Clinical Trials Sarah J. Sinclair is currently running

Image of trial facility.

Lomustine + Standard Therapy

for Glioblastoma

This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's DNA and may kill tumor cells. Radiation therapy uses high energy x-ray photons to kill tumor cells and shrink tumors. Adding lomustine to standard chemotherapy with temozolomide and radiation therapy may shrink or stabilize glioblastoma.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Selumetinib + Olaparib

for Ovarian and Endometrial Cancer

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2

More about Sarah J. Sinclair

Clinical Trial Related6 years of experience running clinical trials · Led 80 trials as a Principal Investigator · 27 Active Clinical Trials
Treatments Sarah J. Sinclair has experience with
  • Paclitaxel
  • Pembrolizumab
  • Carboplatin
  • Fluorouracil
  • Olaparib
  • Radiation Therapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Sarah J. Sinclair specialize in?
Is Sarah J. Sinclair currently recruiting for clinical trials?
Are there any treatments that Sarah J. Sinclair has studied deeply?
What is the best way to schedule an appointment with Sarah J. Sinclair?
What is the office address of Sarah J. Sinclair?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security